Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG)

BACKGROUND: Colorectal cancer (CRC) is a disease of the elderly. However, geriatric patients are often excluded from clinical trials. The combination of capecitabine, oxaliplatin and bevacizumab (XELOX/BEV) has not been assessed in an elderly population. METHODS: We conducted a phase II study of XEL...

Descripción completa

Detalles Bibliográficos
Autores principales: Vamvakas, Lambros, Matikas, Alexios, Karampeazis, Athanasios, Hatzidaki, Dora, Kakolyris, Stelios, Christophylakis, Charalampos, Boukovinas, Ioannis, Polyzos, Aris, Georgoulias, Vassilis, Souglakos, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000321/
https://www.ncbi.nlm.nih.gov/pubmed/24755296
http://dx.doi.org/10.1186/1471-2407-14-277

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000321/
https://www.ncbi.nlm.nih.gov/pubmed/24755296
http://dx.doi.org/10.1186/1471-2407-14-277

Ejemplares similares